FDA approves dispersible dolutegravir/abacavir/3TC for children
On 30 March 2022, the US FDA approved a single tablet regimen of dolutegravir/abacavir/3TC in a dispersible formulation for children weighing 10 kgs to 25 kgs.
This will provide a simpler and easier to take option for children living with HIV.
ViiV Healthcare. ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV. (30 March 2022).